KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) Leases (2019 - 2025)

Biomarin Pharmaceutical's Leases history spans 11 years, with the latest figure at $4.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 20.21% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, down 20.21%, and an annual FY2025 reading of $4.0 million, down 20.21% over the prior year.
  • Leases for Q4 2025 was $4.0 million at Biomarin Pharmaceutical, down from $5.1 million in the prior quarter.
  • The five-year high for Leases was $34.9 million in Q4 2022, with the low at $3.3 million in Q4 2023.
  • Average Leases over 5 years is $11.1 million, with a median of $5.1 million recorded in 2024.
  • Year-over-year, Leases skyrocketed 325.0% in 2022 and then crashed 90.43% in 2023.
  • Tracing BMRN's Leases over 5 years: stood at $8.2 million in 2021, then skyrocketed by 325.0% to $34.9 million in 2022, then crashed by 90.43% to $3.3 million in 2023, then soared by 51.69% to $5.1 million in 2024, then dropped by 20.21% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Leases are $4.0 million (Q4 2025), $5.1 million (Q4 2024), and $3.3 million (Q4 2023).